Amendment To Cervical Cancer Bill Would Require HPV Labeling For Condoms
This article was originally published in The Gray Sheet
Condoms manufactured 180 days after the enactment of breast and cervical cancer treatment legislation pending in the House would require a statement in labeling that condoms do not provide adequate protection against the transmission of human papillomavirus (HPV), according to an amendment unanimously adopted by the House Commerce Committee during its Oct. 29 mark-up of the legislation.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.